The reiteration of an Overweight rating and a high price target by a reputable analyst like Josh Schimmer suggests a strong vote of confidence in CG Oncology's potential. This could lead to increased investor interest and potentially drive the stock price up in the short term, as market participants often react positively to such analyst endorsements.